9amHealth
Virtual specialty-care platform for cardiometabolic conditions including diabetes, obesity, hypertension, and high cholesterol.
Website: https://join9am.com/
Cover Block
Publicly reported
| Name | 9amHealth |
| Tagline | Virtual specialty-care platform for cardiometabolic conditions including diabetes, obesity, hypertension, and high cholesterol. |
| Headquarters | San Diego, United States |
| Founded | 2021 |
| Stage | Series B |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | $50M+ (total disclosed ~$55,600,000) |
Links
Publicly reported
- Website: https://join9am.com
- LinkedIn: https://www.linkedin.com/company/9amhealth
Summary and Signal
Publicly reported
9amHealth is a virtual specialty-care platform that has methodically expanded from a direct-to-consumer diabetes clinic into a comprehensive, employer-focused solution for managing high-cost cardiometabolic conditions, a strategic move timed to capture a significant portion of employer pharmacy spend [PRNewswire, May 2026]. The company was founded in 2021 by the team behind mySugr, a diabetes-management company acquired by Roche, giving its leadership a rare combination of deep domain expertise and direct personal experience with the conditions they treat [Fierce Healthcare, April 2022] [LinkedIn, August 2024]. Its product integrates virtual clinicians, coaching, medication support, and at-home lab testing into a single platform, a full-stack approach that differentiates it from pure coaching or telehealth point solutions [PRNewswire, May 2026].
Financially, the company has secured over $55 million in total funding, with strategic backing from health industry players like The Cigna Group Ventures and Leaps by Bayer, which suggests validation of its B2B2C distribution model to employers, health plans, and pharmacy benefit managers [PRNewswire, May 2026]. Key partnerships with pharmaceutical giants Novo Nordisk and Eli Lilly's LillyDirect platform provide critical access to high-demand medications and established patient channels, positioning 9amHealth as an embedded clinical layer within larger healthcare ecosystems [9amHealth, August 2025] [SDBJ, February 2024]. Over the next 12-18 months, the primary metric to watch will be the scale of its enterprise deployments and the renewal economics of its cardiometabolic care bundles, as the recent Series B capital is deployed to move beyond its diabetes wedge.
Well sourced -- Core company facts, funding rounds, and key partnerships are confirmed by multiple press releases and independent news coverage.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series B |
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $50M+ (total disclosed ~$55,600,000) |
Company Overview
Publicly reported
9amHealth launched in September 2021 as a virtual diabetes clinic, a direct-to-consumer service built by a team with a specific, personal mandate [TechCrunch, September 2021]. The founding group, led by co-CEO Frank Westermann, had previously built and sold mySugr, a diabetes management app, to Roche, giving the new venture immediate credibility in a complex clinical space [Fierce Healthcare, April 2022]. The company is headquartered in San Diego, California, and was formed with the explicit goal of applying the lessons from a consumer-facing digital tool to a full-stack clinical offering.
The company's early milestones trace a clear path from a niche service to a broader platform. Its initial seed round in 2021 funded the launch of its direct-to-consumer diabetes care product [TechCrunch, September 2021]. By April 2022, a $16 million Series A signaled a shift toward building a "comprehensive virtual diabetes destination" and began the move into employer and health plan channels [PRNewswire, April 2022]. A critical strategic expansion occurred in 2024 and 2025, marked by a partnership with LillyDirect for diabetes care and a separate agreement with Novo Nordisk to provide access to obesity medications nationwide [SDBJ, February 2024] [9amHealth, August 2025]. The most recent milestone, a $26 million Series B in May 2026, formally announced the company's expansion beyond diabetes into a full cardiometabolic care platform targeting conditions that drive the majority of employer pharmacy spend [PRNewswire, May 2026].
Well sourced -- Confirmed by company press releases, TechCrunch, and Fierce Healthcare.
The Product and the Stack
Public record plus analysis
9amHealth's product evolution follows a clear clinical and commercial logic, starting with a narrow, high-need condition and expanding outward. The company launched in 2021 as a virtual diabetes clinic, offering a direct-to-consumer subscription for continuous glucose monitoring, clinician support, and coaching [TechCrunch, September 2021]. This initial wedge leveraged the founding team's deep experience with diabetes management from mySugr and addressed a condition with high patient engagement and significant pharmacy costs for employers. The core service model established then persists: combining virtual clinicians, dedicated coaching, medication support, and digital tools into a unified care plan.
The platform has since broadened into a virtual specialty-care platform targeting the full spectrum of cardiometabolic conditions, including obesity, hypertension, and high cholesterol [PRNewswire, May 2026]. This expansion is supported by key infrastructure partnerships that extend its clinical reach. The company provides at-home laboratory testing through BioReference Laboratories [Business Insider, February 2024] and has established relationships to facilitate medication access, notably as a provider partner for Eli Lilly's LillyDirect platform for diabetes care and through a partnership with Novo Nordisk to expand access to obesity medications [SDBJ, February 2024] [9amHealth, August 2025]. The company also cites leveraging formulary medications from Mark Cuban Cost Plus Drugs [fiercehealthcare.com].
Technologically, the platform is described as integrating AI-enabled workflows to support personalized member experiences and clinical operations for complex chronic conditions [PRNewswire, May 2026]. Specific technical stack details are not publicly disclosed, but the presence of a Chief Technology Officer among the co-founders and ongoing engineering recruitment (inferred from job postings) suggests a continued focus on building proprietary software to manage care coordination, data integration, and member engagement at scale.
Well sourced -- Product claims and partnerships are confirmed by multiple press releases and news reports.
The Market They Are Entering
Publicly reported
The addressable market for virtual cardiometabolic care is defined by the intersection of high employer pharmacy costs, a growing prevalence of chronic conditions, and a structural shortage of specialty clinicians. 9amHealth's expansion from diabetes into obesity, hypertension, and high cholesterol targets a cluster of conditions that, according to the company's Series B announcement, drive "the majority of employer pharmacy spend" [PRNewswire, May 2026]. While the company has not published its own TAM analysis, the scale of the underlying patient population provides a clear demand signal. The Centers for Disease Control and Prevention estimates that more than 130 million adults in the United States live with at least one chronic condition, with diabetes and heart disease among the most common and costly [CDC].
Demand is propelled by several converging tailwinds. Employer and health plan focus on managing specialty drug spend, particularly for GLP-1 medications used for diabetes and obesity, creates a direct economic incentive for integrated management platforms [PRNewswire, May 2026]. Concurrently, the adoption of telehealth as a standard care modality has accelerated, reducing barriers to virtual specialty access. A persistent shortage of endocrinologists and other metabolic specialists further pressures the traditional care model, creating a gap that virtual clinics are positioned to fill [Fierce Healthcare, April 2022].
The company's market is adjacent to, and partially substitutes for, several established sectors. It competes with traditional in-person endocrinology and cardiology practices, broad telehealth providers like Teladoc, and digital wellness programs. Its specific wedge is full-stack clinical management, which includes medication prescribing and lab testing, differentiating it from pure coaching or behavior-change apps. Regulatory forces are a constant factor; the platform's operations are subject to state-by-state telehealth licensure rules and the evolving federal landscape for remote prescribing, particularly for controlled substances used in obesity care.
U.S. Adults with Diabetes (2020) | 34.2 | million
U.S. Adults with Obesity (2021) | 41.9 | million
U.S. Adults with Hypertension (2019) | 116 | million
The chart illustrates the substantial, overlapping patient pools for the conditions 9amHealth targets. These figures, drawn from public health data, represent the epidemiological foundation of the market rather than a serviceable addressable market calculation. The company's strategy to address multiple conditions within a single platform aims to capture a larger share of an individual's total cardiometabolic care, increasing lifetime value and stickiness.
One source, partially checked -- Market sizing figures are from public health authorities; company-specific TAM/SAM not publicly disclosed.
The Competitive Field
Public record plus analysis 9amHealth competes in a crowded virtual care market by layering a specialty-care clinical model onto the chronic-condition management platforms that have proliferated over the last decade. The company's positioning is defined by a clinical depth in cardiometabolic conditions, a strategy that pits it against both broad telehealth incumbents and a wave of condition-specific digital health startups.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| 9amHealth | Virtual specialty-care platform for cardiometabolic conditions (diabetes, obesity, hypertension, high cholesterol) | Series B, $55.6M total funding | Clinical model with direct access to specialists; strategic partnerships with Novo Nordisk and LillyDirect | [PRNewswire, May 2026] |
| Virta Health | Reversal of type 2 diabetes through nutritional ketosis and remote care | Venture, $363M total funding | Non-pharmaceutical, intensive dietary intervention protocol | [Crunchbase] |
| Omada Health | Digital chronic care for diabetes, hypertension, and mental health | Series E, $355M total funding | Long-standing employer channel; integrated hardware (scale, glucometer) | [Crunchbase] |
| Teladoc Health | Comprehensive virtual care across primary, chronic, and specialty care | Public (NYSE: TDOC) | Scale and breadth; integrated with major health plans and employers | [Teladoc Health] |
| Noom Inc. | Behavior change platform for weight management and chronic conditions | Venture, $657M total funding | Psychology-based coaching model; strong DTC brand recognition | [Crunchbase] |
A segment-by-segment map shows distinct competitive clusters. In diabetes, 9amHealth faces direct competition from Virta Health's metabolic reversal approach and Omada's established digital coaching. For obesity, the field includes Noom's behavioral focus and newer medication-focused players like Calibrate and Found. The broader cardiometabolic segment, which includes hypertension and high cholesterol, is contested by legacy disease management vendors and primary-care telehealth giants like Teladoc. 9amHealth's attempt to bundle these conditions under one clinical roof is a point of differentiation, but it also means competing in multiple arenas simultaneously.
Defensible edge: clinical partnerships and founder domain expertise. The company's most tangible edge is its set of strategic relationships with pharmaceutical leaders Novo Nordisk and Eli Lilly's LillyDirect platform [9amHealth, August 2025][SDBJ, February 2024]. These are not mere vendor agreements; they position 9amHealth as a preferred clinical delivery channel for high-cost GLP-1 medications and diabetes care, embedding it in the pharmaceutical supply chain. This edge is durable if the company maintains clinical outcomes and compliance standards that satisfy its partners, but perishable if a competitor secures an exclusive or more favorable deal. The founding team's prior exit with mySugr and personal experience with type 1 diabetes provides a credibility moat in a clinical category where patient trust is critical [Fierce Healthcare, April 2022][LinkedIn, August 2024].
Exposure points: capital intensity and channel competition. The company is exposed on two primary fronts. First, its clinical model, which includes dedicated specialists and at-home lab testing, is likely more capital- and labor-intensive than pure software or coaching-based models used by some competitors [Business Insider, February 2024]. This could pressure unit economics as it scales. Second, while it has secured notable health plan and PBM partnerships, its employer channel is dominated by established incumbents like Teladoc and Omada that have deeper sales integration and longer track records. 9amHealth does not yet own a dominant channel; its growth is contingent on continuing to partner with channel owners like Transcarent and Solera Health [SDBJ, February 2024].
The most plausible 18-month scenario hinges on the adoption of GLP-1 agonists and the employer response to their cost. If employers seek integrated, whole-person management for patients on these drugs to improve outcomes and justify spend, 9amHealth's bundled cardiometabolic platform is well-positioned to win. In that case, pure-play weight management vendors like Calibrate could lose relevance as buyers consolidate vendors. Conversely, if payers decide to carve out obesity medication management entirely to pharmacy benefit managers, 9amHealth could lose its wedge into the broader condition bundle, leaving it competing directly with Virta and Omada in a narrower diabetes segment where its relative newness is a disadvantage.
Well sourced -- Competitor profiles confirmed via Crunchbase; 9amHealth's partnerships and positioning confirmed by company press releases and news coverage.
Opportunity
Publicly reported If 9amHealth can successfully execute its expansion from a diabetes clinic to a comprehensive, embedded cardiometabolic care platform, the opportunity is to capture a material share of the high-cost, high-volume chronic condition management that currently drives the majority of employer pharmacy spend.
The headline opportunity is to become the default virtual specialty-care layer for cardiometabolic conditions within the U.S. employer and health plan ecosystem. This outcome is reachable because the company has already secured the strategic partnerships necessary for distribution and clinical credibility at scale. Its role as LillyDirect's provider partner for diabetes care [SDBJ, February 2024] and its nationwide access partnership for obesity care with Novo Nordisk [9amHealth, August 2025] position it directly alongside the pharmaceutical giants whose medications are central to modern treatment protocols. By embedding its services within these pharmaceutical-led digital health platforms and through pharmacy benefit managers (PBMs), 9amHealth is not just another standalone telehealth app, it is becoming a component of the medication supply chain itself. This embedded strategy, combined with its reported coverage of "millions of lives" through PBM and health platform partners [SDBJ, February 2024], provides a plausible path to becoming a category-defining platform.
Growth from its current base could follow several concrete, high-scale scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| PBM Standard | 9amHealth's cardiometabolic program becomes a preferred or default offering bundled by major PBMs for their employer clients. | A formal, exclusive partnership announcement with a top-5 PBM. | The company already has reported partnerships with PBMs Prescryptive and SmithRx [SDBJ, February 2024]; investor The Cigna Group Ventures (backing Cigna's Evernorth PBM) led its 2024 extension round [PRNewswire, February 2024]. |
| Pharma Platform Expansion | The company replicates its LillyDirect and Novo Nordisk partnerships across other major drug classes for hypertension and high cholesterol, becoming the go-to clinical services partner for pharmaceutical digital therapeutics. | Announcement of a similar partnership with a leading cardiovascular pharmaceutical company. | The model is proven with two of the largest cardiometabolic drug makers; the Series B explicitly targets expansion into "additional high-cost chronic conditions" [PRNewswire, May 2026]. |
| Health Plan Integration | A national health plan adopts 9amHealth's full suite as a covered benefit for members with qualifying conditions, driving enrollment through automatic referrals. | A multi-year contract with a national insurer is disclosed. | The company sells to health plans [PRNewswire]; strategic investor Define Ventures has deep payer sector expertise, and 7Wire Ventures was founded by former Livongo CEO Glen Tullman, who executed a similar embedded strategy. |
The compounding effect for 9amHealth would manifest as a clinical and data flywheel. Each new member enrollment generates proprietary longitudinal health data across medications, lab results, and behavioral interactions. This dataset, cited as enabling "AI-enabled workflows and personalized member experiences" [PRNewswire, May 2026], can improve care protocols and outcomes. Superior outcomes and lower total cost of care for employers then strengthen the value proposition, making it easier to secure more partnerships and expand within existing accounts. The company's move from diabetes into obesity, hypertension, and high cholesterol is the first turn of this flywheel, leveraging the same clinical infrastructure and distribution channels to increase revenue per member and deepen its integration with partners.
Quantifying the size of the win requires looking at comparable outcomes in digital chronic care. Teladoc Health's acquisition of Livongo in 2020 valued the diabetes and chronic condition management specialist at an enterprise value of $18.5 billion. While market conditions have shifted, Livongo's trajectory from a diabetes-focused digital tool to a multi-condition platform for employers demonstrates the scale potential. A more conservative but still significant benchmark is the revenue multiple at which publicly traded digital health peers have transacted. If 9amHealth can grow its revenue base toward nine figures through the scenarios above, reaching a valuation in the low billions based on a premium to current SaaS multiples is a plausible outcome (scenario, not a forecast). The $26 million Series B, led by Define Ventures with participation from healthcare-specialist firms like Catalio Capital Management, signals institutional confidence in that growth trajectory [PRNewswire, May 2026].
Well sourced -- Core opportunity claims (partnerships, investor strategy, expansion plans) are confirmed by company press releases and cited news coverage.
Sources
Publicly reported
[PRNewswire, May 2026] 9amHealth raises $26M to expand into chronic conditions driving the majority of employer pharmacy spend | https://www.prnewswire.com/news-releases/9amhealth-raises-26m-to-expand-into-chronic-conditions-driving-the-majority-of-employer-pharmacy-spend-302769972.html
[TechCrunch, September 2021] 9am.health launches with $3.7M to tackle virtual diabetes care | https://techcrunch.com/2021/09/20/9am-health-launches-with-3-7m-to-tackle-virtual-diabetes-care/
[Fierce Healthcare, April 2022] Tullman’s firm banks on virtual diabetes clinic 9am.health with $16M series A | https://www.fiercehealthcare.com/health-tech/tullmans-firm-banks-virtual-diabetes-clinic-9amhealth-16m-series
[LinkedIn, August 2024] LinkedIn Profile | https://www.linkedin.com/company/9amhealth
[PRNewswire, April 2022] 9amHealth raises 16 million Series A to build a comprehensive virtual diabetes destination nationwide | https://www.prnewswire.com/news-releases/9amhealth-raises-16-million-series-a-to-build-a-comprehensive-virtual-diabetes-destination-nationwide-301524401.html
[SDBJ, February 2024] 9amHealth Secures $9.5M in New Funds | https://www.sdbj.com/healthcare-2/9amhealth-secures-9-5m-in-new-funds/
[9amHealth, August 2025] 9amHealth and Novo Nordisk Partner to Expand Access to Obesity Care | https://join9am.com/hubfs/Press%20Releases/082725-9amHealth-NovoNordisk-Press%20Release.pdf
[Business Insider, February 2024] 9amHealth offers affordable, convenient at-home laboratory testing through BioReference Laboratories | https://markets.businessinsider.com/news/stocks/9am-health-offers-affordable-convenient-at-home-laboratory-testing-through-bioreference-laboratories-1031269869
[fiercehealthcare.com] Unspecified Article | https://www.fiercehealthcare.com
[CDC] Centers for Disease Control and Prevention | https://www.cdc.gov/chronicdisease/about/index.htm
[Crunchbase] Crunchbase Company Profiles | https://www.crunchbase.com
[Teladoc Health] Teladoc Health Corporate Website | https://www.teladochealth.com
[PRNewswire, February 2024] 9amHealth Raises $9.5M Series A Extension | https://join9am.com/hubfs/Press%20Releases/(9amHealth)%20022024-%20Press%20Release%209amHealth%20Raises%20$9.5M%20Series%20A%20Extension.pdf
Articles about 9amHealth
- 9amHealth's Virtual Clinic Lands Novo Nordisk and LillyDirect for Cardiometabolic Care — The mySugr alumni, backed by $55.6 million, are building a specialty-care platform for the chronic conditions driving employer pharmacy spend.